GILD Stock Research, Signals & Filings
Drillr aggregates AI research, SEC filings, earnings signals, alt-data and financial tables for GILD. 3 published articles.
Latest Research
LLY: $2.3B Ajax Buy Hedges Mounjaro Patent Cliff
Eli Lilly's $2.3 billion Ajax Therapeutics acquisition reveals a critical divergence in large-cap pharma M&A strategy that the market has mispriced. While Merck and Pfizer scramble to replace patent cliff revenue with expensive blockbuster acquisitions, Lilly is buying rare-disease optionality from a position of GLP-1 strength. Long LLY versus short MRK/PFE targets 8-12% relative return over six months as earnings reveal the cost of desperate dealmaking.
LLYMRKPFEGILD's $5B Tubulis Deal: Oncology ADC Bet as HIV Growth Slows — Undervalued or Overpaid?
Gilead's $5B Tubulis acquisition on April 9, 2026, targets oncology ADCs to complement HIV strength, backed by $9.5B FCF and undervalued multiples. Shares edged up 0.75% amid pipeline promise, but clinical success is key to unlocking upside.
GILD's $5B Tubulis Deal: Can This Acquisition Finally Unlock Its Oncology Turnaround?
Gilead's $5B Tubulis acquisition announced April 7, 2026, targets ADC tech to bolster oncology amid HIV strength. Solid finances support close, but regulatory and execution risks linger. Bullish for pipeline diversification and undervalued stock.
Track GILD with Drillr
SEC filings, earnings calls, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try drillr.ai for free